Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
Assessed by RV013 · Clinical Chair in Health Services Research
Assessed on 16 Nov 2025
OverallReviewer's overall integrity assessment, derived from all research questions Some concerns
DOI 10.1136/bmj-2024-081557 (opens in new tab)
Resource ripekg:research-integrity-assessment/RIPEA237F9DCBC31EFBBD
5 Research Questions · 32 Evidence Items
Q1.1 — Does the study have an associated retraction?
Rationale: No journal webpage notice
Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?
Rationale: No journal webpage notice
Q1.3 — Do other studies by the research team highlight causes for concern?
Rationale: Maybe matches are by chance
Supporting Evidence (30)
Retraction NoticeSource: Retraction Watch database
Optimal power flow of receiving power network considering distributed generation and environment pollution
10.1109/appeec.2010.5448323 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 14964
Rationale: Breach of Policy by Author;Date of Article and/or Notice Unknown;Notice - Limited or No Information
About Author: Hui Chang
Retraction NoticeSource: Retraction Watch database
Variations in different polycystic ovary syndrome phenotypes in a population of Chinese Han
10.1530/ec-13-0080 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 22368
Rationale: Lack of Approval from Author
About Author: Rong Huang
Retraction NoticeSource: Retraction Watch database
Epigenetic Regulation of Cardiac Progenitor Cells Marker c-kit by Stromal Cell Derived Factor-1α
10.1371/journal.pone.0247094 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 25763
Rationale: Copyright Claims;Duplication of/in Image
About Author: Rong Huang
Q2.2 — Are there concerns relating to the timing or absence of study registration?
Rationale: Recruitment started well after registration
Supporting Evidence (2)
Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)
Registration ID: NCT02512315
Registry: ClinicalTrials.gov
Registry Link: https://clinicaltrials.gov/study/NCT02512315 (opens in new tab)
Registration Date: 27-07-2015
Prospective:Whether the trial was registered before participant recruitment began Yes
Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates Registration date is on or before LLM recruitment start date.
Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text
Recruitment Start: 23-02-2016
Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date Setting: 'Six sites in China from 23 February 2016 to 18 February 2019. '
Recruitment End: 18-02-2019
Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date Setting: 'Six sites in China from 23 February 2016 to 18 February 2019.'
Study End: N/A
Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date No explicit study end date found. The last follow-up date was reported as March 1, 2024, but this is not the study end date.
Overall — What is the overall integrity assessment of the study?
Rationale: Authors need to be checked out for instittuions